NO20053960L - Piperidin-benzensulfonamidderivater - Google Patents
Piperidin-benzensulfonamidderivaterInfo
- Publication number
- NO20053960L NO20053960L NO20053960A NO20053960A NO20053960L NO 20053960 L NO20053960 L NO 20053960L NO 20053960 A NO20053960 A NO 20053960A NO 20053960 A NO20053960 A NO 20053960A NO 20053960 L NO20053960 L NO 20053960L
- Authority
- NO
- Norway
- Prior art keywords
- lower alkyl
- unsubstituted
- halogen
- substituted
- heteroaryl
- Prior art date
Links
- DOJJUFZZEBGVRH-UHFFFAOYSA-N benzenesulfonamide;piperidine Chemical compound C1CCNCC1.NS(=O)(=O)C1=CC=CC=C1 DOJJUFZZEBGVRH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- -1 -NR'R " Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 230000007074 memory dysfunction Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03003526 | 2003-02-17 | ||
| PCT/EP2004/001211 WO2004072034A1 (en) | 2003-02-17 | 2004-02-10 | Piperidine-benzenesulfonamide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053960D0 NO20053960D0 (no) | 2005-08-25 |
| NO20053960L true NO20053960L (no) | 2005-08-31 |
Family
ID=32864937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053960A NO20053960L (no) | 2003-02-17 | 2005-08-25 | Piperidin-benzensulfonamidderivater |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7176316B2 (de) |
| EP (1) | EP1594840B1 (de) |
| JP (1) | JP4368375B2 (de) |
| KR (1) | KR100729878B1 (de) |
| CN (1) | CN100372838C (de) |
| AR (1) | AR043187A1 (de) |
| AT (1) | ATE340782T1 (de) |
| BR (1) | BRPI0407543A (de) |
| CA (1) | CA2515838A1 (de) |
| CL (1) | CL2004000250A1 (de) |
| CO (1) | CO5580803A2 (de) |
| DE (1) | DE602004002567T2 (de) |
| DK (1) | DK1594840T3 (de) |
| ES (1) | ES2271844T3 (de) |
| HR (1) | HRP20050708A2 (de) |
| IL (1) | IL170128A (de) |
| MX (1) | MXPA05008749A (de) |
| MY (1) | MY141229A (de) |
| NO (1) | NO20053960L (de) |
| NZ (1) | NZ541537A (de) |
| PL (1) | PL378559A1 (de) |
| PT (1) | PT1594840E (de) |
| RU (1) | RU2330842C2 (de) |
| SI (1) | SI1594840T1 (de) |
| TW (1) | TWI293297B (de) |
| WO (1) | WO2004072034A1 (de) |
| ZA (1) | ZA200506341B (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101230034A (zh) | 2000-03-06 | 2008-07-30 | 阿卡蒂亚药品公司 | 用于治疗5-羟色胺相关性疾病的氮杂环化合物 |
| NZ571695A (en) | 2001-12-28 | 2010-02-26 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| CA2490397A1 (en) | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| MXPA06004305A (es) * | 2003-10-23 | 2006-06-05 | Hoffmann La Roche | Derivados de triaza-espiropiperidina para uso como inhibidores del transformador de glicina 1 en tratamiento de enfermedades neurologicas y neuropsiquiatricas. |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| BRPI0516063A (pt) | 2004-09-27 | 2008-08-19 | Acadia Pharm Inc | sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas |
| JP2008521821A (ja) * | 2004-11-29 | 2008-06-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン受容体のモジュレーター |
| KR100880093B1 (ko) | 2004-12-09 | 2009-01-23 | 에프. 호프만-라 로슈 아게 | 페닐-피페라진 메탄온 유도체 |
| WO2006067414A2 (en) * | 2004-12-23 | 2006-06-29 | Glaxo Group Limited | Glycine transport inhibitors |
| GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
| PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
| US7485637B2 (en) | 2005-01-04 | 2009-02-03 | Hoffmann-La Roche Inc. | Benzoyl-tetrahydropiperidine derivatives |
| EP1838701A1 (de) * | 2005-01-18 | 2007-10-03 | Elan Pharmaceuticals Inc. | N-substituierte heterocyclische sulfonamide |
| WO2006105035A2 (en) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| HRP20151078T1 (hr) | 2006-03-22 | 2015-11-20 | F. Hoffmann - La Roche Ag | Pirazoli kao 11-beta-hsd-1 |
| TW200808695A (en) | 2006-06-08 | 2008-02-16 | Amgen Inc | Benzamide derivatives and uses related thereto |
| DE602007008237D1 (de) * | 2006-06-08 | 2010-09-16 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| US8420670B2 (en) | 2007-08-22 | 2013-04-16 | Abbott Laboratories | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy |
| MX2010010773A (es) | 2008-04-01 | 2011-04-11 | Abbott Gmbh & Co Kg | Tetrahidroisoquinolinas, composiciones farmaceuticas que las contienen y su uso en terapia. |
| GB0817379D0 (en) * | 2008-09-23 | 2008-10-29 | Merck Sharp & Dohme | New use |
| ES2445143T3 (es) * | 2009-01-27 | 2014-02-28 | F. Hoffmann-La Roche Ag | Piperidinas sustituidas por aroilamino y heteroaroilamino como inhibidores de GLYT-1 |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US8524909B2 (en) * | 2010-02-02 | 2013-09-03 | Hoffmann-La Roche Inc. | Tetrahydro-pyran derivatives |
| US8877794B2 (en) | 2010-08-13 | 2014-11-04 | Abbott Laboratories | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8846743B2 (en) | 2010-08-13 | 2014-09-30 | Abbott Laboratories | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9045459B2 (en) | 2010-08-13 | 2015-06-02 | AbbVie Deutschland GmbH & Co. KG | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9309200B2 (en) | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US8853196B2 (en) | 2011-08-05 | 2014-10-07 | AbbVie Deutschland GmbH & Co. KG | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| MX2014006004A (es) | 2011-11-18 | 2015-04-16 | Abbvie Deutschland | Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9650334B2 (en) | 2013-03-15 | 2017-05-16 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9656955B2 (en) | 2013-03-15 | 2017-05-23 | Abbvie Inc. | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP3057960B1 (de) | 2013-10-17 | 2019-02-27 | AbbVie Deutschland GmbH & Co. KG | Aminochroman-, aminothiochroman- und amino-1,2,3,4-tetrahydrochinolin-derivate, pharmazeutische zusammensetzungen damit und verwendung in der therapie |
| MX2016004934A (es) | 2013-10-17 | 2016-12-20 | Abbvie Deutschland | Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia. |
| US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
| ITUA20162545A1 (it) * | 2016-04-13 | 2017-10-13 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di intermedi utili nella sintesi di farmaci |
| US10954224B2 (en) * | 2017-06-13 | 2021-03-23 | Purdue Research Foundation | Delta-opioid receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718405A1 (de) * | 1977-04-26 | 1978-11-02 | Boehringer Sohn Ingelheim | Neue n- eckige klammer auf 1-(3-benzoylpropyl)-4-piperidyl eckige klammer zu -sulfonsaeureamide und verfahren zu deren herstellung |
| RU2216540C2 (ru) * | 1997-11-18 | 2003-11-20 | Тейджин Лимитед | Производные циклических аминов, способ ингибирования |
| JP4388228B2 (ja) * | 1998-02-19 | 2009-12-24 | 興和株式会社 | 環状アミド化合物 |
| PL342818A1 (en) * | 1998-03-06 | 2001-07-02 | Janssen Pharmaceutica Nv | Glycin transport inhibitors |
| EP1296950A2 (de) * | 2000-04-20 | 2003-04-02 | NPS Allelix Corp. | Aminopiperidine zur verwendung als glyt-1-inhibitoren |
| AR028948A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| MXPA04001016A (es) * | 2001-08-03 | 2004-05-27 | Schering Corp | Derivados de sulfonamida como inhibidores de la gamma secretasa. |
-
2004
- 2004-02-10 BR BRPI0407543-9A patent/BRPI0407543A/pt not_active IP Right Cessation
- 2004-02-10 AT AT04709611T patent/ATE340782T1/de active
- 2004-02-10 WO PCT/EP2004/001211 patent/WO2004072034A1/en not_active Ceased
- 2004-02-10 SI SI200430092T patent/SI1594840T1/sl unknown
- 2004-02-10 RU RU2005128775/04A patent/RU2330842C2/ru not_active IP Right Cessation
- 2004-02-10 CA CA002515838A patent/CA2515838A1/en not_active Abandoned
- 2004-02-10 PL PL378559A patent/PL378559A1/pl not_active Application Discontinuation
- 2004-02-10 ES ES04709611T patent/ES2271844T3/es not_active Expired - Lifetime
- 2004-02-10 NZ NZ541537A patent/NZ541537A/en unknown
- 2004-02-10 PT PT04709611T patent/PT1594840E/pt unknown
- 2004-02-10 DK DK04709611T patent/DK1594840T3/da active
- 2004-02-10 KR KR1020057015027A patent/KR100729878B1/ko not_active Expired - Fee Related
- 2004-02-10 JP JP2006500025A patent/JP4368375B2/ja not_active Expired - Fee Related
- 2004-02-10 EP EP04709611A patent/EP1594840B1/de not_active Expired - Lifetime
- 2004-02-10 MX MXPA05008749A patent/MXPA05008749A/es active IP Right Grant
- 2004-02-10 HR HR20050708A patent/HRP20050708A2/xx not_active Application Discontinuation
- 2004-02-10 CN CNB2004800043995A patent/CN100372838C/zh not_active Expired - Fee Related
- 2004-02-10 DE DE602004002567T patent/DE602004002567T2/de not_active Expired - Lifetime
- 2004-02-11 TW TW093103192A patent/TWI293297B/zh active
- 2004-02-12 CL CL200400250A patent/CL2004000250A1/es unknown
- 2004-02-13 US US10/778,560 patent/US7176316B2/en not_active Expired - Fee Related
- 2004-02-16 MY MYPI20040492A patent/MY141229A/en unknown
- 2004-02-16 AR ARP040100468A patent/AR043187A1/es unknown
-
2005
- 2005-08-04 IL IL170128A patent/IL170128A/en not_active IP Right Cessation
- 2005-08-08 ZA ZA200506341A patent/ZA200506341B/en unknown
- 2005-08-12 CO CO05080405A patent/CO5580803A2/es not_active Application Discontinuation
- 2005-08-25 NO NO20053960A patent/NO20053960L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053960L (no) | Piperidin-benzensulfonamidderivater | |
| NO20061419L (no) | Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser | |
| DE69835877D1 (de) | Trizyklische verbindungen | |
| NO20060975L (no) | 1-Benzoyl-piperazinderivater som glycin gjenopptaksinhibitorer for behandling av psykoser | |
| NO20072833L (no) | Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom | |
| NO20062370L (no) | Amidderivater | |
| WO2006034833A1 (en) | Cyclic diarly ureas suitable as tyrosine kinase inhibitors | |
| DE69530094D1 (de) | Thiazolidindione derivate, ihre herstellung und verwendung | |
| NO20081435L (no) | N-oksider som prodroger for piperazin- og piperidinderivater | |
| WO2005040345A3 (en) | 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase | |
| NO20075477L (no) | Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni | |
| SE8102220L (sv) | Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel | |
| JO2235B1 (en) | Derivatives of phenyl | |
| ATE449082T1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor | |
| MXPA04003278A (es) | Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. | |
| DE602004025935D1 (de) | Histondeacetylaseinhibitor und verfahren zu dessen herstellung | |
| SE8804688D0 (sv) | Substituerade styrenderivat | |
| BRPI0418375A (pt) | derivados de diaza-espiropiperidina | |
| EP1568697A4 (de) | 1,3-benzothiazinonderivate, deren herstellungsverfahren und verwendung | |
| DE60202970D1 (de) | Substituierte alkylaminopyridazinonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ATE8389T1 (de) | Amino-alkoxy-pyrazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| DE3060143D1 (en) | N-azolyl acetic acid anilides, process for their preparation and their use as herbicides | |
| SE8405430L (sv) | 7-acylindolforeningar, lempade som mellanprodukter vid synteser av 7-acylindolin-2-oner | |
| DE69613783D1 (de) | 4-(6-fluor-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-on-derivate,ihre herstellung und ihre verwendung in der behandlung von psychosen, schizophrenie und angstzuständen | |
| PT75793A (de) | Neue 1-furyl-3,4-dihydroisochinoline diese enthaltende arzneimittel sowie verfahren zu deren herstellung und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |